Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar pathogenesis and histopathology but a different etiology and epidemiology. NASH and ASH are advanced stages of non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD). NAFLD is characterized by excessive fat accumulation in the liver (steatosis), without any other evident causes of...

Non-alcoholic fatty liver disease is now recognized as the hepatic component of the metabolic syndrome. Non-alcoholic fatty liver disease is a spectrum of fat-associated liver conditions that can result in end-stage liver disease and the need for liver transplantation. Simple steatosis, or fatty liver, occurs early in non-alcoholic fatty liver disease and may progress to non-alcoholic steatohep...

Non-alcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent due to the worldwide obesity epidemic and currently affects one-third of adults or about one billion people worldwide. NAFLD is predicted to affect over 50% of the world's population by the end of the next decade. It is the most common form of liver disease and is associated with increased risk for progression to a mor...

Chronic liver injury, as observed in non-alcoholic steatohepatitis (NASH), progressive fibrosis, and cirrhosis, remains poorly treatable. Steatohepatitis causes hepatocyte loss part by a direct lipotoxic insult, which is amplified derangements the non-parenchymal cellular (NPC) interactive network wherein hepatocytes reside, including, hepatic stellate cells, sinusoidal endothelial cells macrop...

Non-alcoholic fatty liver disease (NAFLD) is a major cause of worldwide, affecting up to 30% adults. Progression non-alcoholic steatohepatitis (NASH) key risk factor for cirrhosis, hepatocellular carcinoma and cardiovascular events. Alterations in reproductive hormones are linked the development and/or progression NAFLD/NASH women. Women with Polycystic Ovary Syndrome (PCOS) those estrogen defi...

Background: Non-alcoholic steatohepatitis (NASH) is an emerging disease belonging to the non-alcoholic fatty liver disease (NAFLD) spectrum, which may progress to fibrosis and thereby to cirrhosis of the liver. Currently, no definitive and effective treatment strategies have been identified to treat NASH. Objective: To study the effect of pioglitazone, quercetin, and hydroxy citric acid on lipi...